similar evolution of cellular hiv-1 dna level in darunavirritonavir monotherapy versus triple therapy in monoi –anrs136 trial over 96 weeks类似的hiv - 1细胞dna的进化水平darunavirritonavir单一疗法和三联疗法monoi -anrs136试验超过96周.pdfVIP

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks 1 1 1 1 1 Sidonie Lambert-Niclot *, Philippe Flandre , Marc-Antoine Valantin , Cathia Soulie , Slim Fourati , 1 1 2 3 4 Marc Wirden , Sophie Sayon , Sophie Pakianather , Laurence Bocket , Bernard Masquelier , 5 1 1 1 Georges Dos Santos , Christine Katlama , Vincent Calvez , Anne-Genevieve Marcelin ´ ˆ ` 1 AP-HP, Pitie-Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France, 2 INSERM U 943, Paris, France, 3 CHRU de Lille, Virology, Lille, France, 4 AP-HP, Pellegrin Hospital, Bordeaux, France, 5 Centre Hospitalier et Universitaire de Fort-de-France, Fort de France, Martinique, France Abstract Background: A higher proportion of intermittent viremia (to have a HIV-1 RNA viral load.50 copies/mL not confirmed) was reported in the boosted protease inhibitor monotherapy arm in some studies including MONOI trial, and that could have an impact on the replenishment of the HIV-1 DNA reservoirs. The HIV-1 DNA level is an interesting marker which reflects the size of cellular HIV reservoir. Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study. Methodology/Principal Findings: This sub-study is focused on 160 patients (79